Cancer Therapy

Anticancer therapy in combination with current cancer treatments awarded European patent

Published in Cancer Weekly, March 19th, 2002

The European Patent and Trademark Office has granted to the Board of Regents of the University of Texas System European Patent No. 0 760 675 titled "Compositions Comprising DNA Damaging Agents and p53," according to Introgen Therapeutics, Inc., (INGN) and the UT Board of Regents .

The patent relates to methods and compositions that combine the potency of DNA damaging agents, such as chemotherapy, with the delivery of a tumor suppressor gene. This patent is one of numerous patents, pending or issued, that Introgen has licensed exclusively from The University of Texas System based on technology from the University of Texas M. D. Anderson Cancer Center.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-03-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry